Despite the revenue growth, Forian reported a net loss of $(1.8) million, or $(0.06) per share, for the fourth quarter, compared to a net income of $0.2 million, or $0.01 per share, in the prior year. For the full year, the company recorded a net loss of $(2.9) million, or $(0.09) per share, an improvement from a net loss of $(3.8) million, or $(0.12) per share, in 2024.
CEO Max Wygod stated, "In 2025, we demonstrated that disciplined cost management and strategic investment can go hand in hand. We grew our business, expanded into new markets, and made targeted investments in our data platform and product development while maintaining a cost-conscious approach that preserved the strength of our balance sheet."
The company also highlighted its achievements in revenue guidance, driven by key contract renewals that offset churn and data supply headwinds. Forian's adjusted EBITDA for the fourth quarter was $(0.2) million, compared to $0.1 million in the prior year, indicating ongoing challenges in operational execution despite revenue growth.
Looking ahead, Forian remains focused on strengthening its data platform and partnerships, expanding its footprint in the pharmaceutical and biotech sectors, and addressing upstream data supply challenges. The company is also in discussions regarding a non-binding proposal from a consortium led by its CEO to acquire all outstanding shares not currently owned by the consortium, although no assurance of a transaction has been provided.
Overall, while Forian's revenue growth is a positive indicator, the net losses and operational challenges suggest a cautious outlook for investors.
